Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Significant response to targeted treatment with alectinib for intramedullary pediatric spinal high-grade glioma with ALK fusion
  • +2
  • Amit Ringel,
  • Ronit Elhasid,
  • Shlomi Constantini,
  • Jonathan Roth,
  • Rina Dvir
Amit Ringel
Tel Aviv Sourasky Medical Center

Corresponding Author:[email protected]

Author Profile
Ronit Elhasid
Tel Aviv Sourasky Medical Center
Author Profile
Shlomi Constantini
Tel Aviv Sourasky Medical Center
Author Profile
Jonathan Roth
Tel Aviv Sourasky Medical Center
Author Profile
Rina Dvir
Tel Aviv Sourasky Medical Center
Author Profile

Abstract

Intramedullary spinal cord high-grade gliomas are rare and almost always fatal pediatric tumors. The current treatment paradigms are surgery, and radiotherapy. This is the first description of a toddler with an intramedullary cervical high-grade glioma harboring an anaplastic lymphoma kinase (ALK) fusion (KIF5B) whose treatment with the ALK inhibitor, alectinib, achieved clinical and radiological evidence of complete remission after six months of treatment. Our findings suggest that ALK inhibitors may emerge as an effective therapy in malignant spinal tumors with a dismal prognosis.